Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

PHASE3TerminatedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

April 4, 2009

Primary Completion Date

April 15, 2010

Study Completion Date

April 15, 2010

Conditions
Skin Diseases, Infectious
Interventions
DRUG

PTK 0796

PTK 0796 100 mg for injection; PTK 0796 tablet 150 mg

DRUG

linezolid

For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution

DRUG

moxifloxacin

moxifloxacin 400 mg tablet; moxifloxacin 400 mg IV infusion solution

Trial Locations (7)

31406

Paratek Recruiting Site, Savannah

31904

Parateck Recruiting Site, Columbus

91942

Parateck Recruiting Site, La Mesa

92056

Paratek Recruiting Site, Oceanside

92114

Paratek Recruiting Site, San Diego

92708

Paratek Recruiting Site, Fountain Valley

95154

Paratek Recruiting Site, San Jose

Sponsors
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Paratek Pharmaceuticals Inc

INDUSTRY